Four positive clinical updates, a billion-dollar licensing deal, a surprising positive opinion for one company in the EU, and a rough NYSEArca debut for one biopharma are this week’s top biotech stories.
Four positive clinical updates, a billion-dollar licensing deal, a surprising positive opinion for one company in the EU, and a rough NYSEArca debut for one biopharma are this week’s top biotech stories.